healthcare · stock-sale · committee-conflict

Ways and Means Member Mike Kelly Unloads Abbott Labs in Rare Trade

The Pennsylvania Republican sold the healthcare giant alongside other blue chips, marking his first transaction in the ticker.

2026-08-26 — Mike Kelly · ABT

Key facts

Rep. Mike Kelly (R-Pa.) recently executed a rare personal stock transaction, divesting from healthcare giant Abbott Laboratories just one day after the company posted strong second-quarter earnings.

According to congressional disclosures, Kelly sold between $1,001 and $15,000 of Abbott Laboratories (ABT) stock on July 17, 2026. Under the rules of the STOCK Act, members of Congress are required to disclose their financial transactions within 45 days, and all transactions are reported in ranges rather than exact amounts. Kelly filed his disclosure 26 days later on August 12.

The timing of the trade directly followed a significant corporate catalyst. On July 16, 2026, Abbott Laboratories filed an 8-K report with the SEC, announcing its second-quarter financial results and raising its full-year adjusted earnings-per-share guidance. The next day, Kelly sold his shares at approximately $100.68. Since the sale, Abbott's stock has risen 15.3% to $116.13, meaning the representative missed out on a post-earnings rally.

While the trade represents a first-time ticker for Kelly, our analysis scored the trade a modest 38 out of 100, suggesting a routine portfolio rebalance rather than a policy-informed transaction. Crucially, the Abbott transaction was executed as part of a same-day batch of three trades, which also included sales of Disney (DIS) and PepsiCo (PEP). Executing multiple trades across different sectors on the same day typically points to broad portfolio reallocation.

Nonetheless, the trade's sector overlap with Kelly’s legislative duties remains notable. Kelly serves on the House Committee on Ways and Means, where he chairs the Tax Subcommittee and sits on the Subcommittee on Health. The Health Subcommittee holds direct oversight over Medicare and Medicaid reimbursement policies, which fundamentally impact the profit margins of medical device and pharmaceutical companies like Abbott.

Just two days prior to the trade, on July 15, the Ways and Means Committee held a scheduled markup session. However, there is no evidence that the bills under consideration during that session had any direct bearing on Abbott's business operations. Furthermore, corporate insider activity at Abbott was mixed around the time of the trade; while a director purchased shares in May, Abbott Executive Vice President Louis Morrone disclosed his own sale of 5,850 shares on August 11.

For a representative who averages fewer than one trade per month, any portfolio adjustment is an event. But in this case, the trade appears to be a standard case of selling the news.

In the end, even congressional tax chairs sometimes just want to rebalance their portfolios.

Sources

  1. Abbott Laboratories Q2 2026 Earnings 8-K — SEC EDGAR
  2. House Ways and Means Markup Schedule — Congress.gov
  3. Louis H. Morrone Form 4 Insider Sale — SEC EDGAR

All stories · Mike Kelly · ABT